<DOC>
	<DOCNO>NCT00281632</DOCNO>
	<brief_summary>This study design find effective safe GW786034 , treatment epithelial ovarian , fallopian tube , primary peritoneal cancer respond standard treatment .</brief_summary>
	<brief_title>A Phase II , Open-Label Study Evaluating Effect Of GW786034 In Subjects With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis epithelial ovarian , fallopian tube primary peritoneal carcinoma . Has receive one prior platinumbased chemotherapy regimen ( cisplatin , carboplatin , oxaliplatin ) . Has psychological , familial , sociological geographical condition permit compliance protocol . Is specifically prohibit medication require medication treatment GW786034 . Exclusion criterion : Has surgery , chemotherapy , hormonal therapy , biologic , immunotherapy , radiotherapy last 28 day recover prior therapy . Poorly control hypertension ( systolic 140mmHg high Diastolic 90mmHg high ) . Currently take warfarin . Low molecular weight heparin lowdose warfarin ( 1mg per day ) permit .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Ovarian epithelial cancer</keyword>
	<keyword>Peritoneal cancer</keyword>
</DOC>